Rucaparib Maintenance Elicits PFS Benefit in Newly Diagnosed Ovarian Cancer

Patients with newly diagnosed advanced ovarian cancer who responded to first-line chemotherapy and were then treated with rucaparib (Rubraca) maintenance therapy experienced a sustained and significant improvement in progression-free survival (PFS)…

This is an article written by Courtney Flaherty and published in OncLive June 24, 2024. Click title to read entire article.

Olaparib Treatment Before Surgery Proves Feasible in BRCA-Mutant Ovarian Cancer

Neoadjuvant treatment with olaparib (Lynparza) prior to surgical resection and adjuvant chemotherapy was well tolerated and led to a 100% optimal resection rate in patients with newly diagnosed, BRCA-mutant ovarian, primary peritoneal, or fallopian tube cancer…

This is an article by Carolyn Seymour published on OncLive Mar. 28, 2023. Click title to read entire article.

COM701 Plus BMS-986207/Nivolumab Shows Early Activity in Platinum-resistant Ovarian Cancer

A triplet regimen comprised of COM701, BMS-986207, and nivolumab (Opdivo) was found to have encouraging antitumor activity and favorable tolerability in patients with heavily pretreated, platinum-resistant ovarian cancer.

This is an article by Ryan Scott published in OncLive Jan. 12, 2023. Click title to read entire article.

Dana-Farber Research Supports FDA Approval of New Therapy for Certain Patients with Ovarian Cancer

Mirvetuximab soravtansine has been approved by the FDA for the treatment of recurrent platinum-resistant high-grade serous ovarian cancer that highly expresses the folate receptor alpha. Clinical testing of this new therapy has been co-led by Dr Ursula Matulonis, MD.

This is a news release published by Dana Farber Cancer Institute on Nov. 14, 2022. Click title to read entire article.

FDA Approves Mirvetuximab Soravtansine For Treatment of Ovarian Cancer

On November 14, 2022, the FDA granted accelerated approval to mirvetuximab soravtansine for the treatment of adult patients with folate receptor α (Frα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1 to 3 prior systemic treatment regimens.

This is an article written by Kristi Rosa and published in OncLive Nov. 15, 2022. Click title to read entire article.

Pembrolizumab Delivers Promising Results in Advanced Clear Cell Gynecologic Cancer

Pembrolizumab (Keytruda) monotherapy induced durable clinical outcomes in heavily pretreated patients with clear cell gynecologic cancer (CCGC), according to findings from the phase 2 PEACOCC trial (NCT03425565).

This is an article written by Jason Harris and published in OncLive Oct. 17, 2022. Click title to read entire article.

Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status

Frontline niraparib (Zejula) maintenance sustained a progression-free survival (PFS) benefit in patients with advanced ovarian cancer, according to updated data from the phase 3 PRIMA trial presented at the 2022 ESMO Congress.

This is an article written by Ryan Scott and published in OncLive Oct. 12, 2022. Click title to read entire article.

Study could help recommend the best treatment for women with early-stage mucinous ovarian cancer

A global study into mucinous ovarian cancer could help oncologists recommend the best treatment for women who are diagnosed early with the condition.

This is an article reviewed by Emilie Henderson, B.Sc., and published on The Clarity Foundation website on  Oct. 12, 2022. Click title to read entire article.

Two New Studies Help Improve the Understanding of Ovarian Cancer

Two new discoveries led by Cedars-Sinai Cancer investigators help improve the understanding of what drives the development of ovarian cancer and why some women’s tumors do not respond to therapy.

This is an article reviewed Emilie Henderson, B.Sc., and published on News-Medical.Net  Oct. 11, 2022. Click title to read entire article.

Niraparib Maintenance Provides Durable Long-term Remission in High-Risk Advanced Ovarian Cancer

Maintenance treatment with niraparib (Zejula) produced a sustained and durable progression-free survival (PFS) benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups, according to updated data from the phase 3 PRIMA trial….

This is an article written by Kristi Rosa and published in OncLive Sept. 15, 2022. Click title to read entire article.